Sangamo BioSciences Announces Presentation At The 2015 Piper Jaffray Healthcare Conference

Sangamo BioSciences Announces Presentation At The 2015 Piper Jaffray Healthcare Conference
Edward Lanphier to Also Participate in the Genetic Rx Conference in Boston

RICHMOND, Calif., Nov. 23, 2015 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO), a leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic^® development programs and an overview of the company's business strategy at 1:00pm ET on Wednesday, December 2, 2015, at the 27^th Annual Piper Jaffray Healthcare Conference. The conference is being held in New York.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The webcast will be archived on the Sangamo website for two weeks after the event.
Edward Lanphier will also participate in the Genetic Rx conference taking place at Harvard Medical School on Thursday, December 3, 2015. Genetic Rx, a networking conference of the Boston Biotech Conferences series, will bring together prominent academics, leaders of the biopharmaceutical industry and key investors to discuss the present and future of genetic therapies, pricing, reimbursement, the regulatory landscape and the treatment of patients with rare and ultra-rare genetic diseases. The event will not be webcast.
About SangamoSangamo BioSciences, Inc. is focused on Engineering Genetic Cures^TM for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic genome editing and gene regulation. The Company has a Phase 2 clinical program to evaluate the safety and efficacy of novel ZFP Therapeutics^® for the treatment of HIV/AIDS (SB-728). Sangamo's other therapeutic programs are focused on monogenic and rare diseases. The Company has formed a strategic collaboration with Biogen Inc. for hemoglobinopathies, such as sickle cell disease and beta-thalassemia, and with Shire International GmbH to develop therapeutics for Huntington's disease. It has also established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at www.sangamo.com.